Efficacy of Mezigdomide Plus Dexamethasone and Bortezomib or Carfilzomib in Patients with Relapsed/Refractory Multiple Myeloma by Line of Therapy: Results from the Phase 1/2 CC-92480-MM-002 Trial
Albert Oriol, Paul Richardson, Marc S. Raab, Darrell White, Richard Leblanc, Noopur Raje, Enrique M. Ocio, Aurore Perrot, Thierry Façon, Cesar Rodriguez Valdes, Ralph Wäsch, Meletios A Dimopoulos, Jing Gong, Shudi Li, Tiziana Civardi, Phillip J. Koo, Erica Petrlik, Jessica Katz, Irwindeep Sandhu (2025). Efficacy of Mezigdomide Plus Dexamethasone and Bortezomib or Carfilzomib in Patients with Relapsed/Refractory Multiple Myeloma by Line of Therapy: Results from the Phase 1/2 CC-92480-MM-002 Trial. , 25, DOI: https://doi.org/10.1016/s2152-2650(25)03458-5.
